Publications by authors named "Andi R Masters"

Claim this Profile
R
Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor.
Anbukkarasi Muniyandi, Gabriella D Hartman, Kamakshi Sishtla, Ratan Rai, Cátia Gomes, Andi R Masters

Angiogenesis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Alyssa C Flint, Dana K Mitchell, Steven P Angus, Abbi E Smith, Waylan Bessler, Andi R Masters

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Alyssa C Flint, Dana K Mitchell, Steven P Angus, Abbi E Smith, Waylan Bessler, Andi R Masters

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.
Adrian L Oblak, Zackary A Cope, Sara K Quinney, Ravi S Pandey, Carla Biesdorf, Andi R Masters

Alzheimers Dement (N Y)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.
Benjamin M Wahle, Eric T Hawley, Yongzheng He, Abbi E Smith, Jin Yuan, Andi R Masters

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis